Discovery of CP-690,550: A Potent and Selective Janus Kinase (JAK) Inhibitor for the Treatment of Autoimmune Diseases and Organ Transplant Rejection

被引：287

作者：

Flanagan, Mark E. ^{[1
]}

Blumenkopf, Todd A. ^{[2
]}

Brissette, William H. ^{[3
]}

Brown, Matthew F. ^{[1
]}

Casavant, Jeffrey M. ^{[1
]}

Shang-Poa, Chang ^{[4
]}

Doty, Jonathan L.

Elliott, Eileen A. ^{[1
]}

Fisher, Michael B. ^{[5
]}

Hines, Michael ^{[1
]}

Kent, Craig ^{[1
]}

Kudlacz, Elizabeth M. ^{[2
]}

Lillie, Brett M. ^{[1
]}

Magnuson, Kelly S. ^{[2
]}

McCurdy, Sandra P. ^{[1
]}

Munchhof, Michael J. ^{[1
]}

Perry, Bret D. ^{[1
]}

Sawyer, Perry S. ^{[1
]}

Strelevitz, Timothy J. ^{[1
]}

Subramanyam, Chakrapani ^{[1
]}

Sun, Jianmin ^{[1
]}

Whipple, David A. ^{[6
]}

Changelian, Paul S. ^{[7
]}

机构：

[1] Pfizer Global Res & Dev, Groton Labs, Groton, CT 06340 USA

[2] Pfizer Global Res & Dev, New London, CT 06320 USA

[3] Yale Univ, New Haven, CT 06520 USA

[4] Univ Connecticut, Dept Stat, Storrs, CT 06269 USA

[5] Boehringer Ingelheim Pharmaceut Inc, Ridgefield, CT 06877 USA

[6] Univ Kansas, Del Shankel Struct Biol Ctr, Lawrence, KS 66047 USA

[7] Lycera Corp, Plymouth, MI 48170 USA

来源：

JOURNAL OF MEDICINAL CHEMISTRY | 2010年 / 53卷 / 24期

关键词：

SEVERE COMBINED IMMUNODEFICIENCY; RHEUMATOID-ARTHRITIS; ALLOGRAFT-REJECTION; GAMMA-CHAIN; CP-690550; IMMUNOSUPPRESSANT; CYTOKINES; MUTATION; SAFETY; IL-2;

D O I：

10.1021/jm1004286

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

There is a critical need for safer and more convenient treatments for organ transplant rejection and autoimmune disorders such as rheumatoid arthritis. Janus tyrosine kinases (JAK1, JAK3) are expressed in lymphoid cells and are involved in the signaling of multiple cytokines important for various T cell functions. Blockade of the JAK1/JAK3-STAT pathway with a small molecule was anticipated to provide therapeutic immunosuppression/immunomodulation. The Pfizer compound library was screened against the catalytic domain of JAK3 resulting in the identification of a pyrrolopyrimidine-based series of inhibitors represented by CP-352,664 (2a). Synthetic analogues of 2a were screened against the JAK enzymes and evaluated in an IL-2 induced T cell blast proliferation assay. Select compounds were evaluated in rodent efficacy models of allograft rejection and destructive inflammatory arthritis. Optimization within this chemical series led to identification of CP-690,550 1, a potential first-in-class JAK inhibitor for treatment of autoimmune diseases and organ transplant rejection.

引用

页码：8468 / 8484

页数：17

共 43 条

[1] Combined use of the JAK3 inhibitor CP-690,550 with mycophenolate mofetil to prevent kidney allograft rejection in nonhuman primates [J].

Borie, DC ;

Larson, MJ ;

Flores, MG ;

Campbell, A ;

Rousvoal, G ;

Zhang, S ;

Higgins, JP ;

Ball, DJ ;

Kudlacz, EM ;

Brissette, WH ;

Elliott, EA ;

Reitz, BA ;

Changelian, PS .

TRANSPLANTATION, 2005, 80 (12) :1756-1764

[2] Calcineurin-Inhibitor-Free Immunosuppression Based on the JAK Inhibitor CP-690,550: A Pilot Study in De Novo Kidney Allograft Recipients [J].

Busque, S. ;

Leventhal, J. ;

Brennan, D. C. ;

Steinberg, S. ;

Klintmalm, G. ;

Shah, T. ;

Mulgaonkar, S. ;

Bromberg, J. S. ;

Vincenti, F. ;

Hariharan, S. ;

Slakey, D. ;

Peddi, V. R. ;

Fisher, R. A. ;

Lawendy, N. ;

Wang, C. ;

Chan, G. .

AMERICAN JOURNAL OF TRANSPLANTATION, 2009, 9 (08) :1936-1945

[3] Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor [J].

Changelian, PS ;

Flanagan, ME ;

Ball, DJ ;

Kent, CR ;

Magnuson, KS ;

Martin, WH ;

Rizzuti, BJ ;

Sawyer, PS ;

Perry, BD ;

Brissette, WH ;

McCurdy, SP ;

Kudlacz, EM ;

Conklyn, MJ ;

Elliott, EA ;

Koslov, ER ;

Fisher, MB ;

Strelevitz, TJ ;

Yoon, K ;

Whipple, DA ;

Sun, JM ;

Munchhof, MJ ;

Doty, JL ;

Casavant, JM ;

Blumenkopf, TA ;

Hines, M ;

Brown, MF ;

Lillie, BM ;

Subramanyam, C ;

Shang-Poa, C ;

Milici, AJ ;

Beckius, GE ;

Moyer, JD ;

Su, CY ;

Woodworth, TG ;

Gaweco, AS ;

Beals, CR ;

Littman, BH ;

Fisher, DA ;

Smith, JF ;

Zagouras, P ;

Magna, HA ;

Saltarelli, MJ ;

Johnson, KS ;

Nelms, LF ;

Des Etages, SG ;

Hayes, LS ;

Kawabata, TT ;

Finco-Kent, D ;

Baker, DL ;

Larson, M .

SCIENCE, 2003, 302 (5646) :875-878

[4] The amino terminus of JAK3 is necessary and sufficient for binding to the common gamma chain and confers the ability to transmit interleukin 2-mediated signals [J].

Chen, M ;

Cheng, A ;

Chen, YQ ;

Hymel, A ;

Hanson, EP ;

Kimmel, L ;

Minami, Y ;

Taniguchi, T ;

Changelian, PS ;

OShea, JJ .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (13) :6910-6915

[5] Structural and Thermodynamic Characterization of the TYK2 and JAK3 Kinase Domains in Complex with CP-690550 and CMP-6 [J].

Chrencik, Jill E. ;

Patny, Akshay ;

Leung, Iris K. ;

Korniski, Brian ;

Emmons, Thomas L. ;

Hall, Troii ;

Weinberg, Robin A. ;

Gormley, Jennifer A. ;

Williams, Jennifer M. ;

Day, Jacqueline E. ;

Hirsch, Jeffrey L. ;

Kiefer, James R. ;

Leone, Joseph W. ;

Fischer, H. David ;

Sommers, Cynthia D. ;

Huang, Horng-Chih ;

Jacobsen, E. J. ;

Tenbrink, Ruth E. ;

Tomasselli, Alfredo G. ;

Benson, Timothy E. .

JOURNAL OF MOLECULAR BIOLOGY, 2010, 400 (03) :413-433

[6] Assessment of Three Human in Vitro Systems in the Generation of Major Human Excretory and Circulating Metabolites [J].

Dalvie, Deepak ;

Obach, R. Scott ;

Kang, Ping ;

Prakash, Chandra ;

Loi, Cho-Ming ;

Hurst, Susan ;

Nedderman, Angus ;

Goulet, Lance ;

Smith, Evan ;

Bu, Hai-Zhi ;

Smith, Dennis A. .

CHEMICAL RESEARCH IN TOXICOLOGY, 2009, 22 (02) :357-368

[7] JAK-STAT PATHWAYS AND TRANSCRIPTIONAL ACTIVATION IN RESPONSE TO IFNS AND OTHER EXTRACELLULAR SIGNALING PROTEINS [J].

DARNELL, JE ;

KERR, IM ;

STARK, GR .

SCIENCE, 1994, 264 (5164) :1415-1421

[8] PYRROLO[2,3-D]PYRIMIDINES [J].

DAVOLL, J .

JOURNAL OF THE CHEMICAL SOCIETY, 1960, (JAN) :131-138

[9]

Flanagan M. E., 2003, Patent No. [WO 2003048162 A1, 2003048162]

[10]

FLEISCHMANN RM, 2009, ARTHRITIS RHEUM S10, V60, pS718

← 1 2 3 4 5 →